COMPANY PROFILE // THE 014 REPORT
Whitehawk Therapeutics, Inc.
WHWK (Nasdaq) · Formerly: Aadi Bioscience, Inc.; Aerpio Pharmaceuticals, Inc.; ZETA ACQUISITION CORP II
Assembled from 3 government sources in 0.3 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- AmberLEI 549300G3U7TKW1M58L09 registration status is LAPSED (last update 2026-08-05): the legal-entity record has not been renewed.
- InfoGLEIF: no direct parent reported; reporting exception reason NON_CONSOLIDATING.
✓ SEC filings✓ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Whitehawk Therapeutics, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Morristown, NJ; listed as WHWK (Nasdaq).[source] It reported revenue of $7.1 million for the fiscal year ended 2025-12-31.[source] It has filed 72 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G/A, filed 2026-11-16.[source] Its largest institutional holders on 13F filings are ACUTA CAPITAL PARTNERS, LLC, QVT Financial LP, MONTANOVA CAPITAL, LLC (as of 2026-06-30).[source] Seraphix flags 1 item from these records: LEI 549300G3U7TKW1M58L09 registration status is LAPSED (last update 2026-08-05).[source]
- red0
- amber1
- info1
- ACUTA CAPITAL PARTNERS, LLC$21.5M
- QVT Financial LP$21.1M
- MONTANOVA CAPITAL, LLC$19.7M
- ORBIMED ADVISORS LLC$18.0M
- Avoro Capital Advisors LLC$13.1M
- Siren, L.L.C.$10.7M
- KVP Capital Advisors, LP$9.9M
- BlackRock, Inc.$8.8M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- BALL BRYAN · See remarks (Officer) · latest Form 4 2026-03-10 · filing · LinkedIn search
- Dugan Margaret · Chief Medical Officer (Officer) · latest Form 4 2025-12-02 · filing · LinkedIn search
- Giacobello Scott M. · CHIEF FINANCIAL OFFICER (Officer) · latest Form 4 2026-03-10 · filing · LinkedIn search
- Lennon David James · CHIEF EXECUTIVE OFFICER (Director,Officer) · latest Form 4 2026-03-10 · filing · LinkedIn search
- Aghazadeh Behzad · Director,10% owner,Other · latest Form 4 2025-06-16 · filing · LinkedIn search
- Avoro Capital Advisors LLC · Director,10% owner,Other · latest Form 4 2025-06-16 · filing · LinkedIn search
- Avoro Ventures LLC · Director,10% owner,Other · latest Form 4 2025-06-16 · filing · LinkedIn search
- Castelein Caley · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
- Dalal Anupam · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
- Desai Neil · Director · latest Form 4 2025-06-17 · filing · LinkedIn search
- Hirmand Mohammad · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
- Maroun Richard E · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001422142 | source |
| LEI | 549300G3U7TKW1M58L09 | source |
| EIN | 61-1547850 | source |
| Business address (SEC) | 2 HEADQUARTERS PLAZA, MORRISTOWN, NJ, 07960 | source |
Does not exist in the records we hold: UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2018-04-18 · in -3,138 days · LEI next renewal (549300G3U7TKW1M58L09)
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Schrodinger, Inc. · Dugan Margaret
- BeOne Medicines Ltd. · Dugan Margaret
- PTC THERAPEUTICS, INC. · Reeve Emma
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-09 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-09 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-09-10 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-08-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-06-12 filing 8-K items 5.07 · SEC EDGAR
- 2026-06-09 filing EFFECT · SEC EDGAR
- 2026-06-05 filing CORRESP · SEC EDGAR
- 2026-06-05 filing UPLOAD · SEC EDGAR
- 2026-05-29 filing S-3 · SEC EDGAR
- 2026-05-21 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-05-18 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-05-14 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-05-13 filing 8-K items 1.01,3.02,7.01,9.01 · SEC EDGAR
- 2026-05-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-07 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-28 filing DEFA14A · SEC EDGAR
- 2026-04-28 filing ARS · SEC EDGAR
- 2026-04-28 filing Proxy statement · SEC EDGAR
- 2026-04-15 filing 144 · SEC EDGAR
- 2026-04-09 filing 144 · SEC EDGAR
- 2026-04-09 filing 144 · SEC EDGAR
- 2026-04-02 filing 144 · SEC EDGAR
- 2026-03-12 filing S-8 · SEC EDGAR
- 2026-03-12 filing Annual report (10-K) · SEC EDGAR
- 2026-03-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2025-12-02 insider First Form 3/4/5 on record for Dugan Margaret (Chief Medical Officer) · SEC Forms 3/4/5
- 2025-11-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2025-11-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2025-08-07 filing Quarterly report (10-Q) · SEC EDGAR
170 earlier entries
- 2025-08-07 filing 8-K items 2.02,9.01
- 2025-06-17 insider First Form 3/4/5 on record for Desai Neil (Director)
- 2025-06-17 insider First Form 3/4/5 on record for Zhao Baiteng (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Aghazadeh Behzad (Director,10% owner,Other)
- 2025-06-16 insider First Form 3/4/5 on record for Avoro Capital Advisors LLC (Director,10% owner,Other)
- 2025-06-16 insider First Form 3/4/5 on record for Avoro Ventures LLC (Director,10% owner,Other)
- 2025-06-16 insider First Form 3/4/5 on record for Castelein Caley (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Dalal Anupam (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Hirmand Mohammad (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Maroun Richard E (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Reeve Emma (Director)
- 2025-06-13 filing 8-K items 5.07
- 2025-05-22 filing UPLOAD
- 2025-05-13 filing CORRESP
- 2025-05-08 filing Quarterly report (10-Q)
- 2025-05-08 filing 8-K items 2.02,9.01
- 2025-05-07 filing UPLOAD
- 2025-04-28 filing ARS
- 2025-04-28 filing DEFA14A
- 2025-04-28 filing Proxy statement
- 2025-04-25 filing 424B5
- 2025-04-08 filing EFFECT
- 2025-04-04 filing CORRESP
- 2025-04-04 filing UPLOAD
- 2025-04-03 insider First Form 3/4/5 on record for BALL BRYAN (See remarks)
- 2025-04-03 insider First Form 3/4/5 on record for Giacobello Scott M. (CHIEF FINANCIAL OFFICER)
- 2025-04-03 insider First Form 3/4/5 on record for Lennon David James (CHIEF EXECUTIVE OFFICER)
- 2025-03-31 filing S-3
- 2025-03-31 filing 8-K/A items 9.01
- 2025-03-28 filing S-8
- 2025-03-28 filing Annual report (10-K)
- 2025-03-26 filing 8-K items 2.01,9.01
- 2025-03-18 filing 8-K items 2.02,5.03,9.01
- 2025-03-18 filing D
- 2025-03-18 name change Name changed from Aadi Bioscience, Inc.
- 2025-03-06 filing SCHEDULE 13D/A
- 2025-03-05 filing SCHEDULE 13D/A
- 2025-03-04 filing SCHEDULE 13D/A
- 2025-03-04 filing 8-K items 1.01,5.07,7.01,9.01
- 2025-03-03 filing 144
- 2025-03-03 filing 144
- 2025-03-03 filing 144
- 2025-02-24 filing SCHEDULE 13D/A
- 2025-02-19 filing DEFA14A
- 2025-02-18 filing DEFA14A
- 2025-02-05 filing DEFA14A
- 2025-02-04 filing SCHEDULE 13D/A
- 2025-01-31 filing DEFM14A
- 2025-01-30 filing SCHEDULE 13D
- 2025-01-24 filing SCHEDULE 13D/A
- 2025-01-21 filing PREM14A
- 2024-12-31 filing SCHEDULE 13D
- 2024-12-30 filing DEFA14A
- 2024-12-23 filing SCHEDULE 13D/A
- 2024-12-23 filing SCHEDULE 13D/A
- 2024-12-20 filing DEFA14A
- 2024-12-20 officer change 8-K items 1.01,3.02,5.02,7.01,9.01
- 2024-11-06 filing Quarterly report (10-Q)
- 2024-11-06 filing 8-K items 2.02,9.01
- 2024-10-03 filing 144
- 2024-10-01 filing SC 13D/A
- 2024-09-30 filing 8-K items 8.01
- 2024-09-19 officer change 8-K items 5.02,9.01
- 2024-09-03 filing 144
- 2024-08-22 officer change 8-K items 5.02
- 2024-08-21 filing 8-K items 2.05,8.01,9.01
- 2024-08-07 filing Quarterly report (10-Q)
- 2024-08-07 filing 8-K items 2.02,9.01
- 2024-06-12 filing 8-K items 5.07
- 2024-06-03 filing 144
- 2024-05-08 filing Quarterly report (10-Q)
- 2024-05-08 filing 8-K items 2.02,9.01
- 2024-05-03 filing 424B5
- 2024-04-30 filing EFFECT
- 2024-04-26 filing CORRESP
- 2024-04-26 filing ARS
- 2024-04-26 filing DEFA14A
- 2024-04-26 filing Proxy statement
- 2024-04-04 filing 8-K items 1.01
- 2024-03-13 filing Annual report (10-K)
- 2024-03-13 filing 8-K items 2.02,9.01
- 2024-03-01 filing 144
- 2024-02-20 filing UPLOAD
- 2024-02-12 filing S-8
- 2024-02-12 filing S-3
- 2023-12-14 filing 8-K items 8.01,9.01
- 2023-12-01 filing 144
- 2023-11-08 filing Quarterly report (10-Q)
- 2023-11-08 filing 8-K/A items 2.02,9.01
- 2023-11-08 filing 8-K items 2.02,9.01
- 2023-10-02 officer change 8-K items 5.02,7.01,9.01
- 2023-09-01 filing 144
- 2023-08-09 filing Quarterly report (10-Q)
- 2023-08-09 filing 8-K items 2.02,9.01
- 2023-07-03 filing 144
- 2023-06-16 filing 8-K items 5.07
- 2023-05-10 filing Quarterly report (10-Q)
- 2023-05-10 filing 8-K items 2.02,9.01
- 2023-04-28 filing ARS
- 2023-04-28 filing DEFA14A
- 2023-04-28 filing Proxy statement
- 2023-04-03 filing 144
- 2023-03-29 filing S-8
- 2023-03-29 filing Annual report (10-K)
- 2023-03-28 officer change 8-K/A items 5.02
- 2023-03-28 officer change 8-K items 2.02,5.02,9.01
- 2023-03-03 officer change 8-K items 5.02,7.01,9.01
- 2023-01-23 filing 8-K items 1.01
- 2023-01-17 filing SC 13D/A
- 2022-12-07 filing 8-K items 5.03,9.01
- 2022-11-28 filing 8-K items 3.01
- 2022-11-09 filing Quarterly report (10-Q)
- 2022-11-09 officer change 8-K items 2.02,5.02,9.01
- 2022-11-04 filing EFFECT
- 2022-11-04 filing 424B3
- 2022-11-02 filing CORRESP
- 2022-11-01 filing UPLOAD
- 2022-10-26 filing S-3
- 2022-10-11 filing D
- 2022-09-26 filing SC 13D/A
- 2022-09-22 filing 8-K items 1.01,3.02,7.01,9.01
- 2022-08-10 filing Quarterly report (10-Q)
- 2022-08-10 filing 8-K items 2.02,9.01
- 2022-06-30 filing 8-K items 1.02
- 2022-06-17 filing 8-K items 5.07
- 2022-05-12 filing Quarterly report (10-Q)
- 2022-05-12 filing 8-K items 2.02,9.01
- 2022-04-26 filing DEFA14A
- 2022-04-26 filing Proxy statement
- 2022-03-21 filing 424B5
- 2022-03-17 filing 424B5
- 2022-03-17 filing 8-K items 1.01,9.01
- 2022-03-17 filing S-8
- 2022-03-17 filing Annual report (10-K)
- 2022-03-17 filing 8-K items 2.02,9.01
- 2022-01-20 filing 8-K items 1.01
- 2021-11-23 filing 8-K items 8.01,9.01
- 2021-11-12 filing SC 13D/A
- 2021-11-10 filing Quarterly report (10-Q)
- 2021-11-10 filing 8-K items 2.02,9.01
- 2021-11-01 officer change 8-K items 5.02,7.01,9.01
- 2021-10-04 filing 424B3
- 2021-10-01 filing EFFECT
- 2021-09-30 filing CORRESP
- 2021-09-29 filing UPLOAD
- 2021-09-24 filing S-8
- 2021-09-24 filing S-3
- 2021-09-24 filing 8-K/A items 9.01
- 2021-09-20 officer change 8-K items 5.02,7.01,9.01
- 2021-09-13 officer change 8-K items 4.01,5.02,9.01
- 2021-09-10 filing D
- 2021-09-10 filing D
- 2021-09-08 filing SC 13D
- 2021-09-07 filing SC 13D
- 2021-09-03 filing 8-K items 1.01
- 2021-09-03 filing SC 13D/A
- 2021-08-30 filing SC 13D/A
- 2021-08-27 officer change 8-K items 1.01,2.01,3.02,3.03,5.01,5.02,5.03,5.05,9.01
- 2021-08-23 filing 8-K items 1.01,9.01
- 2021-08-23 name change Name changed from Aerpio Pharmaceuticals, Inc.
- 2021-08-18 filing 8-K items 5.07
- 2021-08-11 filing Quarterly report (10-Q)
- 2021-08-11 filing 8-K items 2.02,9.01
- 2021-07-26 filing 8-K items 5.07,7.01,9.01
- 2021-07-08 filing DEFM14A
- 2021-06-21 filing PREM14A
- 2021-06-09 filing DEFA14A
- 2021-06-09 filing Proxy statement
- 2021-06-04 filing DEFA14A
- 2021-06-04 filing 8-K items 7.01,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-09 (within 30 days) 10-Q filed
- 2026-11-09 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-10 (older) 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-08-06 (older) 10-Q filed
- 2026-08-06 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-06-12 (older) 8-K filed: Item 5.07 shareholder vote
- 2026-06-09 (older) EFFECT filed
- 2026-06-05 (older) CORRESP filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:WHWK The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
0 possible matches held apart, matched by name only, not counted above; 5 records under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1422142 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | WHWK / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 549300G3U7TKW1M58L09 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 549300G3U7TKW1M58L09) | GLEIF |
| EIN | 611547850 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001422142 | SEC EDGAR / IRS |
| CUSIP | 00032Q104 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001422142 | SEC EDGAR |
former name (shown apart, not merged) (5)
- former nameAadi Bioscience, Inc. · Connecticut business registrations
- former nameAadi Bioscience, Inc. · ClinicalTrials.gov
- former nameAADI BIOSCIENCE, INC. · State licences
- former nameAADI BIOSCIENCE, INC. · State licences
- former nameAADI BIOSCIENCE, INC. · New York corporations
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $7,145,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-20 05:51 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$20,596,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 05:51 UTC | Report an error |
| Total assets (at 2025-12-31) | $150,830,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 05:51 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $136,311,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 05:51 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $37,568,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 05:51 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 05:51 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 05:51 UTC | Report an error |
| State of incorporation | DE | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 05:51 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 05:51 UTC | Report an error |
| Business address | 2 HEADQUARTERS PLAZA, EAST BUILDING, 11TH FLOOR, MORRISTOWN, NJ, 07960 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 05:51 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 05:51 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$97,433,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 05:51 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $552,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 05:51 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $0 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 05:51 UTC | Report an error |
| Form D total offering amount (D filed 2025-03-18) | $100,002,392 | 2025-03-18 | D | as filed | 2026-11-20 05:51 UTC | Report an error |
| Form D total amount sold (D filed 2025-03-18) | $100,002,392 | 2025-03-18 | D | as filed | 2026-11-20 05:51 UTC | Report an error |
| Form D industry group | Biotechnology | 2025-03-18 | D | as filed | 2026-11-20 05:51 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2025-03-18 | D | as filed | 2026-11-20 05:51 UTC | Report an error |
| Form D date of first sale | 2025-03-04 | 2025-03-18 | D | as filed | 2026-11-20 05:51 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001193125-26-453576
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0001193125-26-453576 | 2026-11-20 05:51 UTC | Report an error |
| Net income (loss) | -$21,209,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0001193125-26-453576 | 2026-11-20 05:51 UTC | Report an error |
| Cash and cash equivalents | $68,973,000 | at 2026-09-30 | 10-Q | 2026-11-09 | 0001193125-26-453576 | 2026-11-20 05:51 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-09 Filing 10-Q filed
- 2026-11-09 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-10 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-08-06 Filing 10-Q filed
- 2026-08-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-06-12 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-06-09 Filing EFFECT filed
- 2026-06-05 Filing CORRESP filed
- 2026-06-05 Filing UPLOAD filed
- 2026-05-29 Filing S-3 filed
- 2026-05-21 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-05-13 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-05-07 Filing 10-Q filed
- 2026-05-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-28 Filing DEFA14A filed
- 2026-04-28 Filing ARS filed
- 2026-04-28 Filing DEF 14A filed
- 2026-03-12 Filing S-8 filed
- 2026-03-12 Filing 10-K filed
- 2026-03-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-11-06 Filing 10-Q filed
- 2025-11-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-08-07 Filing 10-Q filed
- 2025-08-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-06-13 Filing 8-K filed: Item 5.07 shareholder vote
8-K item text, as filed (excerpts)
- 2026-11-09 8-K Item 2.02, Results of Operations and Financial Condition
On November 9, 2026, Whitehawk Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be… the 8-K · retrieved 2026-11-20 05:51 UTC - 2026-08-06 8-K Item 2.02, Results of Operations and Financial Condition
On August 6, 2026, Whitehawk Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be… the 8-K · retrieved 2026-11-20 05:51 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | ACUTA CAPITAL PARTNERS, LLC | $21,461,477 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:51 UTC | Report an error |
| 2 | QVT Financial LP | $21,139,947 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:51 UTC | Report an error |
| 3 | MONTANOVA CAPITAL, LLC | $19,694,000 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:51 UTC | Report an error |
| 4 | ORBIMED ADVISORS LLC | $18,019,076 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:51 UTC | Report an error |
| 5 | Avoro Capital Advisors LLC | $13,050,261 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:51 UTC | Report an error |
| 6 | Siren, L.L.C. | $10,703,927 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:51 UTC | Report an error |
| 7 | KVP Capital Advisors, LP | $9,920,266 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:51 UTC | Report an error |
| 8 | BlackRock, Inc. | $8,806,552 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:51 UTC | Report an error |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | $6,359,609 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:51 UTC | Report an error |
| 10 | ADAR1 Capital Management, LLC | $6,143,585 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:51 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- WHITEHAWK THERAPEUTICS, INC. · LEI 549300G3U7TKW1M58L09 · root
Exhibit 21 subsidiaries: not held yet.
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1422142.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001422142. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.